Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell...

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Diffuse large B-cell lymphoma (DLBCL) frequently overexpresses the MYC oncogene.
• MYC-driven cancers demonstrate sensitivity to DNA damage response (DDR) pathway inhibition.
• The role of the DDR pathway as a therapeutic target in DLBCL requires further investigation.

Purpose of the Study:

• To investigate the DDR pathway as a potential therapeutic target in DLBCL.
• To evaluate the efficacy of checkpoint kinase (CHK) inhibitors in DLBCL models.
• To determine if targeting DDR can induce apoptosis and inhibit proliferation in DLBCL.

Main Methods:

• Immunohistochemical analysis of DDR activation markers (phosphorylated CHK, CDC25c, γH2AX) in 99 DLBCL patients.
• Treatment of DLBCL cell lines and primary cells with CHK inhibitors (PF-0477736 and AZD-7762).
• Assessment of cell proliferation, DNA damage accumulation, and apoptosis following CHK inhibition.

Main Results:

• Approximately 50% of DLBCLs exhibited constitutive DDR activation and DNA damage markers (γH2AX).
• Constitutive γH2AX expression correlated with c-MYC levels and predicted poor outcomes.
• CHK inhibition with PF-0477736 and AZD-7762 effectively hindered proliferation and induced apoptosis in DLBCL cells with activated DDR.

Conclusions:

• Constitutive DDR activation and DNA damage are prevalent in a subset of DLBCLs.
• Pharmacologic inhibition of CHK kinases represents a promising therapeutic strategy for DLBCL.
• Targeting the DDR pathway offers a novel approach for treating MYC-driven DLBCL.